Analysis: Alzheimer's Drug Treamtent Costs Patients $75,000 Per Year

The drug, aducanumab, works by sticking antibodies to plaques in the brain, allowing the body's immune system to come in and remove them.

Alzheimer's patients could pay roughly $75,000 each year for treatment and medical costs related to the IV drug aducanumab (also known as aduhelm), according to new peer-reviewed analysis from the American Academy of Neurology.  

Neurologist Dr. Andrew Budson reviewed the report and provided context to us. 

"The drug itself is expensive, the diagnostic tests are expensive, and the surveillance MRI scans can be costly as well," Budson said.